Statistical Involvement in the Clinical Development of a New Drug

Colton T. : Statistics in Medicine. Little, Brown and Company, Boston, 1974.

Hill A.B. : Principles of Medical Statistics (9th ed.). Oxford University Press, New York, 1971.

Remington R.D. Schork M.A. : Statistics With Applications to the Biological and Health Sciences. Prentice-Hall, Inc., New Jersey, 1970.

Buncher C.R. Tsay J.K. , (eds.): Statistics in the Pharmaceutical Industry. Marcel Dekker, Inc., N.Y. 1981.

A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes sections I and II, University Group Diabetes Program. Diabetes 19(Suppl. 2):747–830, 1970.

Hypertensive detection and follow-up program cooperative group. Five-year findings of the hypertension detection and follow-up program I reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 242:2562–2571, 1979.

Hypertensive detection and follow-up program cooperative group. Five-year findings of the hypertensive detection and follow-up Program II mortality by race, sex and age. JAMA 242:2572–2577, 1979.

Dorr A.E. Gundersen K. Schneider J.C. Jr. Spencer T.W. Martin W.B. : Colestipol hydrochloride in hypercholesterolemic patients—effect on serum cholesterol and mortality. J. Chron. Dis. 31:5–14, 1978.

The Anturane Reinfarction Trial Research Group.: Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. N. Engl. J. Med. 298:289–295, 1978.

The Anturane Reinfarction Trial Research Group.: Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N. Engl. J. Med. 302:250–256, 1980.

The Norwegian Multicenter Study Group.: ***Ti-molol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N. Engl. J. Med. 304:801–807, 1981.

Seltzer H.S. : A summary of criticisms of the findings of the University Group Diabetes Program (UGDP). Diabetes 21:976–979, 1972.

Kilo C. Miller J.P. Williamson J.R. : The archilles heel of the University Group Diabetes Program. JAMA 243:450–457, 1980.

Temple R. Pledger G.W. : The FDA's critique of the anturane reinfarction trial. N. Engl. J. Med. 303:1488–1492, 1980.

Health Education and Welfare, Food and Drug Administration, FDA 77–3040, General Considerations for the Clinical Evaluation of Drugs.

Department of Health and Human Services, Food and Drug Administration, Docket No. 80D-0217, General Statistical Documentation Guide for Protocol Development and NDA Submissions.

Report of an International Conference held at the Ditchley Foundations. The scientific and ethical basis of the clinical evaluation of medicines. Eur. J. Clin. Pharmacol. 18:129–134, 1980.

Gehan E.A. Freireich E.J. : Non-randomized controls in cancer clinical trials. N. Engl. J. Med. 290:198–203, 1974.

Pocock S.J. : Allocation of patients to treatment in clinical trials. Biometrics 35:183–197, 1979.

Pocock S.J. Simon R. : Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103–115, 1979.

Peto R. Pike M.C. Armitage P. Breslow N.E. Cox D.R. Howard S. V. Mantel N. McPherson K. Peto J. Smith P.G. : Design and analysis of randomized clinical trials requiring prolonged observations of each patient. I Introduction and Design. Br. J. Cancer 34:585–612, 1976.

Iglewicz B. Begg C.B. : A treatment allocation procedure for sequential clinical trials. Biometrics 36:81–90, 1980.

Byar D.P. Simon R.M. Friedenwald W.T. Schlesselman J.J. DeMets D.L. Ellenberg J.H. Gail M.H. Ware J. H. : Randomized clinical trials. Prospective on some recent ideas. N. Engl. J. Med. 295:74–80, 1976.

Brown W.B. Jr. : The crossover experiment for clinical trials. Biometrics 36:69–79, 1980.

Snedecor G.W. Cochran W. G. : Statistical Methods (7th ed.). Iowa State University Press, Iowa, 1980.

Steel R.G.D. Torrie J. H. : Principles and Procedures of Statistics (1st ed.). McGraw-Hill Book Co., N.Y., 1960.

Winer B.J. : Statistical Principles in Experimental Design. (1st ed.). McGraw-Hill, N.Y., 1962.

Wagner J.G. : Biopharmaceutics and Relevant Pharmacokinetics (1st ed.). Drug Intelligence Publications, Ill., 1971.

Albert K. S. , (ed.): Drug Absorption and Disposition: Statistical Considerations. American Pharmaceutical Association, 1980.

Feinstein A.R. : Clinical Biostatistics, C.V. Mosby, Mo., 1977.

Feller W. : An Introduction to Probability Theory and Its Applications. (2nd ed.), Wiley and Sons, N.Y., 1957.

Tukey J.W. : Some thoughts on clinical trials, especially problems of multiplicity, Science 198:679–684, 1977.

Elfring G.L. Schultz J.R. : Group sequential designs for clinical trials, Biometrics 29:471–477, 1973.

Pocock S.J. : Group sequential methods in the design and analysis of clinical trials, Biometrika 35:549–556, 1979.

Pocock S.J. : The size of cancer clinical trials and stopping rules, Br. J. Cancer 38:757, 1978.

Canner P. L. : Repeated analysis of clinical trial data, Proc. Int. Biomet. Conf. 1:261–275, 1976.

Canner P.L. : Monitoring treatment differences in long term clinical trials, Biometrics 33:603–615, 1977.

DeMets D.L. Ware J.H. : Group sequential methods for clinical trials with a one-sided hypothesis, Biometrika 67:651–660, 1980.

Stoline M.R. : The status of multiple comparisons in one-way ANOVA designs, Am. Stat. 35:134–141, 1981.

Dunnett C Goldsmith C. : When and how to do multiple comparison, Chapter 16 in Statistics in the Pharmaceutical Industry, eds. Buncher C.R. Tsay J.Y. , M. Dekker Inc., New York, 1981.